Abstract
A genetic test developed by Prescient Medicine can predict individual risk of opioid addiction, the company said, based on studies by the company and a collaboration partner.
In one study, Sherman Chang, Ph.D., VP of research and development at the company’s collaboration partner AutoGenomics, and colleagues, researched the scientific literature to describe genetic variations between opioid-addicted and non-addicted populations, then developed a predictive algorithm to determine opioid addiction risk.
BackyardProduction / Getty Images
In the second clinical study, Chang and colleagues assessed the efficacy of the panel by using it to genotype samples for the 16 SNPs from 70 patients diagnosed with prescription opioid/heroin addiction, and 68 healthy control patients, using a multiplexed film-based microarray technology.
To assess the panel, the researchers carried out a pair of independent clinical studies. In the first, Prescient Medicine researchers led by founder and CEO Keri Donaldson, M.D., compared the frequency of the identified mutations in 37 patients with prescription opioid or heroin addiction to 30 age- and gender-matched patients with no history of addiction, in order to validate that the genes had predictive value.